Budesonide/formoterol (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Budesonide/formoterol" in English language version.

refsWebsite

Global rank English rank

7nih.gov

4^th place

4doi.org

2^nd place

3web.archive.org

1^st place

3fda.gov

447^th place

338^th place

2drugs.com

399^th place

333^rd place

2medicines.org.uk

3,823^rd place

2,387^th place

2europa.eu

68^th place

117^th place

2handle.net

102^nd place

76^th place

2clincalc.com

3,912^th place

2,496^th place

1medicines.ie

low place

1ginasthma.org

low place

1hpra.ie

low place

1delawareonline.com

4,565^th place

2,584^th place

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Budesonide; Formoterol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

delawareonline.com

Haber G (19 November 2006). "AstraZeneca banking on asthma inhaler". Delaware News-Journal (delawareonline). Archived from the original on 30 September 2007. Retrieved 9 July 2020.

doi.org

Jenkins CR, Bateman ED, Sears MR, O'Byrne PM (August 2020). "What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?". Respirology. 25 (8): 804–815. doi:10.1111/resp.13804. PMID 32237004.
Lasserson TJ, Ferrara G, Casali L, et al. (Cochrane Airways Group) (December 2011). "Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children". The Cochrane Database of Systematic Reviews (12): CD004106. doi:10.1002/14651858.CD004106.pub4. PMID 22161385.
Kew KM, Karner C, Mindus SM, Ferrara G, et al. (Cochrane Airways Group) (December 2013). "Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children". The Cochrane Database of Systematic Reviews. 2013 (12): CD009019. doi:10.1002/14651858.CD009019.pub2. PMC 8949777. PMID 24343671.
Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, et al. (April 2018). "Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis". JAMA. 319 (14): 1485–1496. doi:10.1001/jama.2018.2769. PMC 5876810. PMID 29554195.{{cite journal}}: CS1 maint: overridden setting (link)

drugs.com

"Budesonide / formoterol (Symbicort) Use During Pregnancy". Drugs.com. 28 August 2019. Retrieved 13 April 2020.
"Has a generic version of Symbicort been approved?". Drugs.com.

europa.eu

ema.europa.eu

"BiResp Spiromax EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 29 April 2020.
"DuoResp Spiromax EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 29 April 2020.

fda.gov

"Safety Alerts for Human Medical Products - Long-Acting Beta agonists (LABAs) and Inhaled Corticosteroids (ICS): Drug Safety Communication - Boxed Warning About Asthma-Related Death Removed". FDA. Retrieved 23 December 2017.
"FDA Approves First Generic of Symbicort to Treat Asthma and COPD". U.S. Food and Drug Administration (Press release). 15 March 2022. Retrieved 15 March 2022.

accessdata.fda.gov

"Drug Approval Package: Symbicort (budesonide/formoterol fumarate dihydrate) NDA #021929". U.S. Food and Drug Administration (FDA). 30 October 2008. Retrieved 29 April 2020.

ginasthma.org

"Global Strategy for Asthma Management and Prevention" (PDF). Ginasthma.org. 2020. p. 90. Retrieved 9 May 2020. evidence for safety of usual doses of ICS and LABA

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

hpra.ie

"PACKAGE LEAFLET:INFORMATION FOR THE USER Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder budesonide, formoterol fumarate dihydrate" (PDF). hpra.ie - Health Products Regulatory Authority (Irish state agency). July 2015. Archived (PDF) from the original on 9 August 2018.

medicines.ie

"Symbicort Turbohaler 100/6 Summary of Product Characteristics". Medicines.ie. Irish Pharmaceutical Healthcare Association. 2 February 2021. Retrieved 2 July 2021.

medicines.org.uk

"Symbicort Turbohaler 200/6 Inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 30 August 2019. Retrieved 13 April 2020.
"Symbicort Turbohaler 100/6, Inhalation powder - Patient Information Leaflet". Electronic Medicines Compendium. September 2020. Retrieved 9 September 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Jenkins CR, Bateman ED, Sears MR, O'Byrne PM (August 2020). "What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?". Respirology. 25 (8): 804–815. doi:10.1111/resp.13804. PMID 32237004.
Lasserson TJ, Ferrara G, Casali L, et al. (Cochrane Airways Group) (December 2011). "Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children". The Cochrane Database of Systematic Reviews (12): CD004106. doi:10.1002/14651858.CD004106.pub4. PMID 22161385.
Kew KM, Karner C, Mindus SM, Ferrara G, et al. (Cochrane Airways Group) (December 2013). "Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children". The Cochrane Database of Systematic Reviews. 2013 (12): CD009019. doi:10.1002/14651858.CD009019.pub2. PMC 8949777. PMID 24343671.
Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, et al. (April 2018). "Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis". JAMA. 319 (14): 1485–1496. doi:10.1001/jama.2018.2769. PMC 5876810. PMID 29554195.{{cite journal}}: CS1 maint: overridden setting (link)

ncbi.nlm.nih.gov

Kew KM, Karner C, Mindus SM, Ferrara G, et al. (Cochrane Airways Group) (December 2013). "Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children". The Cochrane Database of Systematic Reviews. 2013 (12): CD009019. doi:10.1002/14651858.CD009019.pub2. PMC 8949777. PMID 24343671.
Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, et al. (April 2018). "Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis". JAMA. 319 (14): 1485–1496. doi:10.1001/jama.2018.2769. PMC 5876810. PMID 29554195.{{cite journal}}: CS1 maint: overridden setting (link)

dailymed.nlm.nih.gov

"Symbicort- budesonide and formoterol fumarate dihydrate aerosol". DailyMed. 24 July 2019. Retrieved 29 April 2020.

web.archive.org

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"PACKAGE LEAFLET:INFORMATION FOR THE USER Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder budesonide, formoterol fumarate dihydrate" (PDF). hpra.ie - Health Products Regulatory Authority (Irish state agency). July 2015. Archived (PDF) from the original on 9 August 2018.
Haber G (19 November 2006). "AstraZeneca banking on asthma inhaler". Delaware News-Journal (delawareonline). Archived from the original on 30 September 2007. Retrieved 9 July 2020.